

Press Release

Treatment of Advanced Heart Failure

FineHeart strengthens its Board of Directors with the appointment of Pierre Chauvineau

An international medtech executive to support the company's scale-up

Bordeaux, France – June 2nd, 2026 – FineHeart, a French clinical-stage medtech company developing FlowMaker®, a breakthrough therapy for the treatment of advanced heart failure, announces the appointment of Pierre Chauvineau as a member of its Board of Directors.

This appointment comes at a strategic stage in FineHeart's development, as the company simultaneously accelerates its clinical and industrial programs for FlowMaker® and prepares the next phases of its international expansion. With a recognized profile within the international medtech ecosystem, extensive cardiovascular sector expertise, and a strong track record in supporting innovative companies through structuring, acceleration, and scale-up phases, Pierre Chauvineau's arrival further strengthens FineHeart's experienced governance.

Jean-Luc Boulnois, Chairman of FineHeart's Board of Directors, commented: *"We are delighted to welcome Pierre Chauvineau to our Board of Directors, which is fully committed to supporting FineHeart's development strategy. His profile complements a highly engaged governance team dedicated to advancing FineHeart's ambitions. His international medtech experience, deep understanding of the cardiovascular sector, and expertise in international market access challenges will be valuable assets in supporting the company's scale-up."*

Arnaud Mascarell, Chief Executive Officer and co-founder of FineHeart, added: *"Pierre's arrival marks an important step in supporting our clinical, industrial, and international ambitions. With FlowMaker® at the core of our strategy, we are developing highly differentiated proprietary technology building blocks — including transcutaneous wireless energy and data transfer, implantable electronics, intelligent physiological control, and associated digital technologies — whose potential could extend to other applications in the field of active implantable medical devices. Pierre's experience in bringing innovative medical technologies to market will be particularly valuable for FineHeart ."*

Pierre Chauvineau concluded: *"I am impressed by the quality of the team, the strategic vision driven by FineHeart's management, and the complementarity of the existing Board of Directors. FlowMaker® embodies an exceptional technological and medical ambition aimed at addressing a major clinical need that remains largely unmet. I am delighted to contribute to its success alongside the management team and the Board."*

Pierre Chauvineau's career

With more than 35 years of experience gained within major corporations and high-growth innovative companies, Pierre's career combines operational expertise, strategic vision, leadership, and support for innovative companies in medical technologies and value creation within highly regulated environments.

Throughout his career, Pierre has held senior executive leadership roles at Boston Scientific, Medtronic, and Cameron Health, leading large-scale international operations, including one of Boston Scientific's largest European business units, and contributing to the global launch of innovative medical technologies.

Pierre also has extensive governance experience and a strong track record in supporting rapidly growing innovative companies. He chairs several boards of directors in the medtech and digital health sectors, including Sequana Medical, and actively collaborates with executives, investors, and European innovation programs.

About FlowMaker®

FlowMaker® is the first fully implantable cardiac output accelerator designed for the treatment of advanced heart failure. Positioned entirely within the left ventricle, FlowMaker® works in synergy with the heart's natural contractions to provide physiological support while preserving native blood flow. Its minimally invasive intraventricular beating-heart architecture notably avoids complex aortic bypass procedures. Thanks to its extremely low energy consumption and proprietary transcutaneous wireless energy and data transfer technology without external driveline, FlowMaker® aims to eliminate the constraints associated with current cardiac assist systems, significantly reduce infection risks, and substantially improve patients' quality of life.

About FineHeart

FineHeart is a French clinical-stage medtech company developing innovative solutions for the treatment of advanced heart failure. Founded by Arnaud Mascarell, Dr. Stéphane Garrigue and a team of international cardiology experts, the company is developing FlowMaker®, a disruptive therapy designed to transform the management of advanced heart failure. FineHeart owns an international portfolio of 170 patents, is ISO 13485 certified, and benefits from the support of private, industrial and European institutional investors, notably through the European IPCEI Tech4Cure program, which aims to develop next-generation technologies for active implantable medical devices and digital health.

Contacts

Media Relations

Annie-Florence Loyer
afloyer@newcap.fr
+33 (0) 6 88 20 35 59

Investor Relations

Sébastien Robitaille
Sebastien.robitaille@fine-
heart.com